Xtant Medical (NYSEAMERICAN:XTNT – Get Free Report) announced its earnings results on Monday. The medical device company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01), FiscalAI reports. Xtant Medical had a negative net margin of 10.17% and a negative return on equity of 23.45%. The business had revenue of $24.29 million for the quarter, compared to analysts’ expectations of $25.48 million.
Xtant Medical Stock Down 22.8%
NYSEAMERICAN XTNT opened at $0.21 on Tuesday. Xtant Medical has a 52 week low of $0.17 and a 52 week high of $0.84. The company has a quick ratio of 1.05, a current ratio of 2.16 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $29.43 million, a P/E ratio of -2.62 and a beta of -0.19. The stock’s 50-day moving average price is $0.31 and its 200-day moving average price is $0.44.
Analyst Upgrades and Downgrades
Separately, Loop Capital set a $1.00 price target on shares of Xtant Medical in a research note on Wednesday, September 2nd. Two research analysts have rated the stock with a Buy rating. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $1.00.
Read Our Latest Stock Analysis on Xtant Medical
Xtant Medical Company Profile
Xtant Medical Group, Inc. develops and markets medical products used in spine surgery. Its portfolio includes spinal implant systems and biologic products intended to support bone growth and spinal fusion. The company serves surgeons and healthcare providers, primarily in the United States, and also reaches select international markets through distribution relationships. Its products are used in procedures to treat spinal conditions and support stabilization or fusion. Xtant Medical’s business brings together spinal-device and biologics operations, including products developed through acquisitions.
Read More
- Five stocks we like better than Xtant Medical
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
Receive News & Ratings for Xtant Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical and related companies with MarketBeat.com's FREE daily email newsletter.
